ROS1 rearrangements are potent oncogenic drivers in lung cancer. While identified in <2% of NSCLC, tumours positive for ROS1 rearrangements can be targeted by specific TKIs.
It has been determined that ROS1 rearrangements are not present alongside other oncogenic driver mutations, such as EGFR and ALK, therefore sequential testing is recommended.
Genetics - Cytogenetics
CTGN
Lung cancer ROS1 status
5 days
8065